Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study - Wikidata - wikimedia - TriplyDB

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study

http://www.wikidata.org/entity/Q33343120

about

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use.Development and Validation of a High Performance Liquid Chromatographic Method for Determination of Bimatoprost in Chitosan-Based Ocular Inserts

P2860

Q26741012-2DE9274C-F01B-40F1-AE1B-4E5E6AB9DAD9 Q34570414-56EECD7F-F18F-4DE4-AEBB-7F515B92A048 Q58130580-535FF25C-6F88-4AEE-9938-67330B0555E2

P2860

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study

http://www.wikidata.org/entity/Q33343120

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Comparative study of the stabi ...... st 0.005%: a patient-use study

@ast

Comparative study of the stabi ...... st 0.005%: a patient-use study

@en

type

label

Comparative study of the stabi ...... st 0.005%: a patient-use study

@ast

Comparative study of the stabi ...... st 0.005%: a patient-use study

@en

prefLabel

Comparative study of the stabi ...... st 0.005%: a patient-use study

@ast

Comparative study of the stabi ...... st 0.005%: a patient-use study

@en

P1433

Q33343120-3C89F848-570D-470C-9B5D-DD561F1416E5

P1476

Q33343120-D2373BD6-2ECC-46DA-B523-153CA7268086

P2093

Q33343120-13F9215E-FE91-4FC4-B8B4-3689C3D8D057

Q33343120-BEC05C45-5ABD-43D2-9EBF-7D52E4690FF5

Q33343120-FDD43064-E9BF-49CD-ACE0-EA566AC242DC

P2860

Q33343120-0434F33F-460A-4D22-86D5-0CCE6BB3C58B

Q33343120-0B6D9257-B880-4670-9259-2CEAF303EA02

Q33343120-503A04CC-0C0F-488A-B69A-959D537A1B70

Q33343120-700BE896-BD11-4C2B-81CC-2464ABFE47E5

Q33343120-73A24550-F085-490E-A822-0741265C8CE4

Q33343120-8537C8B5-D315-4F15-A4B8-BD37E6157A0A

Q33343120-8B928E99-F1E4-4B22-830C-A47ADFF1F740

Q33343120-9307333F-6B9A-488C-B23F-C3B484904B1F

Q33343120-9B027A27-7876-4AB2-82A3-B6E752895B3B

Q33343120-AA798BB4-C19B-440F-975F-CF01AFBC9DFF

P2888

Q33343120-CA74FABF-728F-4D8D-BFE1-1B0E0387D3FF

P304

Q33343120-F0744C85-1533-4492-9E4F-120797F8153A

P31

Q33343120-4E5731A7-3370-4701-8621-1E22DF95821A

P356

Q33343120-4AFA2D4B-A17C-4730-A870-211C05065FB1

P478

Q33343120-E99E8BC4-C177-4287-9507-0670F638DED9

P50

Q33343120-9B47F890-6849-4AED-A04F-704841FBC197

P577

Q33343120-D2DCEA5A-0901-4998-A9DD-4FA15DBEB785

P5875

Q33343120-46EF9169-83C3-495C-815E-F4465DDF2BC1

P6179

Q33343120-B635EBD3-5DDE-4107-9319-1A132127C1AD

P698

Q33343120-BC87BD93-C590-41CA-A4E1-F81031C34527

P932

Q33343120-7C46A923-2FEA-4952-90D9-F5C2DE04468B

P356

P1433

BMC Ophthalmology

P1476

Comparative study of the stabi ...... st 0.005%: a patient-use study

@en

P2093

Cristiano C Umbelino

http://www.w3.org/2001/XMLSchema#string

John G Walt

http://www.w3.org/2001/XMLSchema#string

Mauricio D Paolera

http://www.w3.org/2001/XMLSchema#string

P2860

World Map of the Köppen-Geiger climate classification updated

Effect of temperature and light on the stability of latanoprost and its clinical relevance.

Effects of common ophthalmic preservatives on ocular health.

A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension.

Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials.

A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).

P2888

P304

11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2415-8-11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5308608

http://www.w3.org/2001/XMLSchema#string

P6179

1036862106

http://www.w3.org/2001/XMLSchema#string

P698

18547433

http://www.w3.org/2001/XMLSchema#string

P932

2442051

http://www.w3.org/2001/XMLSchema#string